{
    "clinical_study": {
        "@rank": "8119", 
        "acronym": "NGF0112", 
        "arm_group": [
            {
                "arm_group_label": "rhNGF 0.5 \u00b5g/mL Sentinel", 
                "arm_group_type": "Experimental", 
                "description": "1 x 35 \u00b5L drop 3 subjects"
            }, 
            {
                "arm_group_label": "rhNGF 5 \u00b5g/mL Sentinel", 
                "arm_group_type": "Experimental", 
                "description": "1 x 35 \u00b5L drop 3 subjects"
            }, 
            {
                "arm_group_label": "rhNGF 60 \u00b5g/mL Part A", 
                "arm_group_type": "Experimental", 
                "description": "3 x 35 \u00b5L drops applied at 4 h intervals 6 subjects"
            }, 
            {
                "arm_group_label": "rhNGF 20 \u00b5g/mL Sentinel", 
                "arm_group_type": "Experimental", 
                "description": "1 x 35 \u00b5L drop 3 subjects"
            }, 
            {
                "arm_group_label": "rhNGF 20 \u00b5g/mL Part A", 
                "arm_group_type": "Experimental", 
                "description": "3 x 35 \u00b5L drops applied at 4 h intervals 6 subjects"
            }, 
            {
                "arm_group_label": "rhNGF 180 \u00b5g/mL Part A", 
                "arm_group_type": "Experimental", 
                "description": "3 x 35 \u00b5L drops applied at 4 h intervals 6 subjects"
            }, 
            {
                "arm_group_label": "Placebo Part A", 
                "arm_group_type": "Placebo Comparator", 
                "description": "3 x 35 \u00b5L drops applied at 4 h intervals 6 subjects"
            }, 
            {
                "arm_group_label": "rhNGF 20 \u00b5g/mL Part B", 
                "arm_group_type": "Experimental", 
                "description": "3 x 35 \u00b5L drops applied at 4 h intervals per day during 5 consecutive days 9 subject"
            }, 
            {
                "arm_group_label": "rhNGF 20 \u00b5g/mL Part B cohort 0M", 
                "arm_group_type": "Experimental", 
                "description": "3 x 35 \u00b5L drops applied at 4 h intervals per day during 5 consecutive days 3 subjects"
            }, 
            {
                "arm_group_label": "rhNGF 60 \u00b5g/mL Part B", 
                "arm_group_type": "Experimental", 
                "description": "3 x 35 \u00b5L drops applied at 4 h intervals per day during 5 consecutive days 9 subjects"
            }, 
            {
                "arm_group_label": "rhNGF 180 \u00b5g/mL Part B", 
                "arm_group_type": "Experimental", 
                "description": "3 x 35 \u00b5L drops applied at 4 h intervals per day during 5 consecutive days 9 subjects"
            }, 
            {
                "arm_group_label": "Placebo Part B", 
                "arm_group_type": "Placebo Comparator", 
                "description": "3 x 35 \u00b5L drops applied at 4 h intervals per day during 5 consecutive days 10 subjects"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to assess the safety and tolerability of single and\n      multiple ascending doses of rhNGF when administered as eye drops in healthy subjects."
        }, 
        "brief_title": "Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This is a Phase I, randomised, double-masked, placebo-controlled eye drops administration\n      study of rh-NGF in healthy male and female subjects.\n\n      This study consists of a single ascending dose part (part 0 one drop single application).\n      Then single ascending dose part (part A; one drop three times a day) and a multiple\n      ascending dose part (part B; one drop three times a day for five days). All parts of the\n      study will consist of 3 ascending dose levels.\n\n      In order to support the dose escalation MAD phase from Covance, Basel to Covance, Leeds, an\n      additional cohort (0M) will be conducted at Covance, Leeds at the same dose level as cohort\n      1M to ensure a degree of consistency between the two sites, i.e. that no dose escalation\n      stopping criteria were met at either site.\n\n      In Part 0, each ascending dose cohort will include 3 subjects treated with one dose of\n      rh-NGF.\n\n      In part A, each ascending dose cohort will include 6 subjects treated with rh-NGF and 2 with\n      placebo.\n\n      In part B, each ascending dose cohort will include 9 subjects treated with rh-NGF drug and 3\n      with placebo, in addition to cohort 0M, which will include 3 subjects treated with rh-NGF\n      and 1 with placebo"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects, aged between 18 and 60 years, inclusive.\n\n          -  Subject has to be able to communicate well with the investigator, understands and\n             complies with the requirements of the study, and understands and signs the written\n             volunteer informed consent form.\n\n          -  Subject's systemic and ocular medical history must be considered normal in the\n             opinion of the investigator at the Screening and Baseline visits.\n\n          -  Best corrected distance visual acuity (BCDVA) score \u2264 0.00 LogMAR (\u226583 ETDRS letters,\n             20/20 Snellen or 1.0 decimal fraction) in each eye at the Screening and Baseline\n             visits.\n\n          -  Normal anterior segment on external and slit lamp examination in both eyes at the\n             Screening and Baseline visits.\n\n          -  Normal posterior segment on fundus ophthalmoscopic examination in both eyes at the\n             Screening and Baseline visits.\n\n          -  Subject must be considered in good systemic health in the opinion of the investigator\n             at the Screening and Baseline visits, as determined by:\n\n               1. Subject's body mass index is between 18.5 and 30.4 kg/m2 inclusive\n\n               2. A pre-study physical examination with no clinically significant abnormalities.\n\n               3. Vital signs within clinically acceptable ranges for the purposes of the study\n                  (sitting systolic blood pressure [BP] \u2265 90 mmHg and \u2264 150 mmHg; diastolic BP \u2265\n                  50 mmHg and \u2264 95 mmHg; heart rate (pulse rate) \u2265 40 and \u2264 100 beats per minute;\n                  oral body temperature \u2265 35.5\u00b0C and \u2264 37.5\u00b0C).\n\n               4. An ECG with no clinically significant abnormalities, in the opinion of the\n                  Investigator.\n\n               5. Pre-study clinical laboratory findings within normal range or not deemed\n                  clinically significant in the opinion of the investigator if outside of the\n                  normal range\n\n          -  Female subjects will be:\n\n               -  either post menopausal where post menopause is defined as the period following\n                  peri-menopause, i.e. postmenopausal after 12 months without a menstrual period\n                  and with a serum FSH value within the reference range for postmenopausal females\n                  at Screening\n\n               -  or permanently sterilised (e.g. tubal occlusion, hysterectomy, bilateral\n                  salpingectomy)\n\n               -  or be using 2 different forms of highly effective contraception throughout the\n                  study.\n\n        Male subjects with female partners of child-bearing potential must use 2 different forms\n        of highly effective contraception throughout the study and for a further 3 months after\n        the follow-up visit and all male subjects must be willing to avoid donating sperm during\n        this time.\n\n        Exclusion Criteria:\n\n          -  Subject has had a clinically significant illness in the 6 weeks before screening in\n             the opinion of the investigator.\n\n          -  Subject is not suitable to participate in the study in the opinion of the\n             investigator\n\n          -  Subject has participated in any clinical study with an investigational drug/device\n             within 3 months prior to the first day of dosing.\n\n          -  Subject has had a serious adverse reaction or significant hypersensitivity to any\n             drug or chemically related compounds or has a clinically significant allergy to\n             drugs, foods or other materials (in the opinion of the investigator).\n\n          -  Administration of any topical ocular (prescription or over the counter including\n             artificial tears) or systemic medication including herbal product or fish oil\n             preparations within 14 days before the first dose of study drug. Vitamins and mineral\n             supplements not containing other substances are allowed until 96 hours before each\n             dose if considered by the Investigator unlikely to interfere with the study results.\n             Paracetamol at doses of at most 2 grams per day and ibuprofen at doses of at most\n             1200 mg per day for no more than 3 consecutive days or 6 non-consecutive days are\n             allowed. Oral, injectable and implantable hormonal contraceptives are allowed without\n             restrictions for female subjects. Longer exclusion periods apply for:\n\n               1. amiodarone and hydroxychloroquine (210 days),\n\n               2. monoclonal antibodies/ immunoglobulins/ other therapeutic proteins (120 days)\n\n               3. Experimental drugs with a half life known to the Study Unit: Five half lives\n                  plus 2 weeks\n\n               4. Experimental drugs with a half life unknown to the Study Unit: 120 days\n\n               5. chloroquine and flunarizine (100 days)\n\n               6. fluoxetine (75 days),\n\n               7. benzodiazepines different from midazolam, lorazepam and triazolam,\n                  chlorpromazine, mephenytoin, nortryptyline, phenobarbital, primidone,\n                  carbamazepine, phenytoin and phenprocoumon (35 days).\n\n          -  Subject has a significant history of drug/solvent abuse (within the last 2 years) or\n             a positive drugs of abuse test at any time during the study.\n\n          -  Subject has a history of alcohol abuse (within the last 2 years) or currently drinks\n             in excess of 28 units per week or has a positive alcohol breath test at any time\n             during the study.\n\n          -  Subject is a smoker or has smoked in the 6 months prior to dosing.\n\n          -  Subject who has a positive human immunodeficiency virus (HIV) screen, hepatitis B\n             screen or hepatitis C screen.\n\n          -  Subject has donated blood or blood products (e.g., plasma or platelets) within the 3\n             months prior to screening.\n\n          -  Subject has a partner who will be pregnant or breastfeeding during the study\n\n          -  Pregnant or breastfeeding female or those with a positive pregnancy test or who will\n             not use a medically acceptable contraceptive method from selection and during the\n             study\n\n          -  Subject having used any glucocorticosteroid by any route in the last 30 days\n             whichever the route of administration, or any  medication by ocular or nasal\n             administration route from 30 days before screening.\n\n          -  Subjects currently diagnosed with any active ocular disease, even if mild, other than\n             refractive error.\n\n          -  Subject with history of ocular surgery, including laser refractive surgery\n\n          -  Subject using a contact lens within 7 days prior administration of the first dose\n\n          -  Intraocular pressure (IOP) >= 22 mmHg in either eye\n\n          -  Presence of any corneal opacity or corneal fluorescein staining >0.5 grade using the\n             modified Oxford scale\n\n          -  Schirmer's test without anesthesia <= 9 mm/5 minutes\n\n          -  Tear film break up time < 8 seconds"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01744704", 
            "org_study_id": "NGF0112", 
            "secondary_id": "2012-004302-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "rhNGF 0.5 \u00b5g/mL Sentinel", 
                "intervention_name": "rhNGF 0.5 \u00b5g/mL Sentinel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "rhNGF 5 \u00b5g/mL Sentinel", 
                "intervention_name": "rhNGF 5 \u00b5g/mL Sentinel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "rhNGF 20 \u00b5g/mL Sentinel", 
                "intervention_name": "rhNGF 20 \u00b5g/mL Sentinel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "rhNGF 20 \u00b5g/mL Part A", 
                "intervention_name": "rhNGF 20 \u00b5g/mL Part A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "rhNGF 60 \u00b5g/mL Part A", 
                "intervention_name": "rhNGF 60 \u00b5g/mL Part A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "rhNGF 180 \u00b5g/mL Part A", 
                "intervention_name": "rhNGF 180 \u00b5g/mL Part A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "rhNGF 20 \u00b5g/mL Part B", 
                "intervention_name": "rhNGF 20 \u00b5g/mL Part  B", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "rhNGF 20 \u00b5g/mL Part B cohort 0M", 
                "intervention_name": "rhNGF 20 \u00b5g/mL Part B cohort 0M", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "rhNGF 60 \u00b5g/mL Part B", 
                "intervention_name": "rhNGF 60 \u00b5g/mL Part B", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "rhNGF 180 \u00b5g/mL Part B", 
                "intervention_name": "rhNGF 180 \u00b5g/mL Part B", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Part A", 
                "intervention_name": "Placebo Part A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Part B", 
                "intervention_name": "Placebo Part B", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetrahydrozoline", 
                "Mitogens"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Nerve Growth Factor", 
            "Ophthalmic Solutions", 
            "Eye Drops", 
            "rh-NGF"
        ], 
        "lastchanged_date": "May 20, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Allschwil", 
                        "country": "Switzerland", 
                        "zip": "CH - 4123"
                    }, 
                    "name": "Covance Basel Research Unit AG - Lettenweg 118 -"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom", 
                        "zip": "LS2 9LH"
                    }, 
                    "name": "COVANCE CLINICAL RESEARCH UNIT Ltd - Springfield House - Hyde Street"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Switzerland", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "12", 
        "official_title": "A Phase I, Randomised, Double-masked, Placebo-controlled, Combined Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Recombinant Human Nerve Growth Factor Eye Drops in Healthy Male and Female Volunteers", 
        "overall_official": [
            {
                "affiliation": "Covance Basel Research Unit AG - Lettenweg 118 - CH - 4123 Allschwil / Switzerland", 
                "last_name": "Thierry Kamtchoua, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "COVANCE CLINICAL RESEARCH UNIT Ltd - Springfield House - Hyde Street - Leeds - LS2 9LH - UK", 
                "last_name": "Ashley Brooks, MBChB", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Domp\u00e9 s.p.a.Via San Martino, 12 - 20122 Milan, Italy", 
                "last_name": "Pier Adelchi Ruffini, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Domp\u00e9 s.p.a. - Via San Martino, 12 - 20122 Milan, Italy", 
                "last_name": "Mauro P Ferrari, PharmD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Switzerland: Swissmedic", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "A global ocular discomfort score will be determined using a 100 mm visual analogue scale (VAS) on which 0 means no symptoms and 100 means the worst possible discomfort. This evaluation is to be performed before any ophthalmic assessment at a given study visit.  Specific ocular symptoms to be assessed with the VAS  include:foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision,photophobia Part 0: VAS evaluated on days -1, 1, 3, 10 Part A: VAS evaluated on days -1, 1, 3, 10 Part B: VAS evaluated on days -1, 1, 5, 7, 15", 
                "measure": "Change in local ocular tolerability score from screening to Day -1, Day 1, Day 3, Day 5, Day 7, Day 10, Day 15", 
                "safety_issue": "Yes", 
                "time_frame": "Screening, Day -1, Day 1, Day 3, Day 5, Day 7, Day 10, Day 15"
            }, 
            {
                "description": "Slit lamp examination (SLE) to assess the eyelid margin, conjunctiva, cornea, anterior chamber, iris and lens with the instillation of fluorescein to evaluate corneal fluorescein staining (modified Oxford scale) and tear film break-up time Outcome: normal/abnormal Part 0: evaluation at screening and on days -1, 1, 3, 10 Part A: evaluation at screening and on days -1, 1, 3, 10 Part B: evaluation at screening and on days -1, 1, 5, 7, 15", 
                "measure": "Change in slit lamp examination (SLE) from screening to Day -1, Day 1, Day 3, Day 5, Day 7, Day 10, Day 15", 
                "safety_issue": "Yes", 
                "time_frame": "Screening, Day -1, Day 1, Day 3, Day 5, Day 7, Day 10, Day 15"
            }, 
            {
                "description": "Intraocular pressure determination using Goldmann applanation tonometry Outcome: normal/abnormal Part 0: evaluation at screening and on days 3, 10 Part A: evaluation at screening and on days 3, 10 Part B: evaluation at screening and on days 7, 15", 
                "measure": "Change in intraocular Pressure from screening to Day 3, Day 7, Day 10, Day 15", 
                "safety_issue": "Yes", 
                "time_frame": "Screening, Day 3, Day 7, Day 10, Day 15"
            }, 
            {
                "description": "Best corrected distance visual acuity measured using the ETDRS (Early Treatment Diabetic Retinopathy Study) score Outcome: normal/abnormal Part 0: BCDVA evaluated at screening and on days -1, 1, 3, 10 Part A: BCDVA evaluated at screening and on days -1, 1, 3, 10 Part B: BCDVA evaluated at screening and on days -1, 1, 5, 7, 15", 
                "measure": "Change in best corrected distance visual acuity (BCDVA) from screening to Day -1, Day 1, Day 3, Day 5, Day 7, Day 10, Day 15", 
                "safety_issue": "Yes", 
                "time_frame": "Screening, Day -1, Day 1, Day 3, Day 5, Day 7, Day 10, Day 15"
            }, 
            {
                "description": "Dilated fundus ophthalmoscopy to assess the  vitreous, retina/macula/choroid, and optic nerve, including cup/disc ratio Outcome: normal/abnormal Part 0: evaluation at screening and on days 1, 3, 10 Part A: evaluation at screening and on days 1, 3, 10 Part B: evaluation at screening and on days 1, 5, 7, 15", 
                "measure": "Change in dilated fundus ophthalmoscopy from screening to Day 1, Day 3, Day 5, Day 7, Day 10, Day 15", 
                "safety_issue": "Yes", 
                "time_frame": "Screening, Day 1, Day 3, Day 5, Day 7, Day 10, Day 15"
            }
        ], 
        "reference": [
            {
                "PMID": "9748012", 
                "citation": "Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology. 1998 Sep;51(3):695-702."
            }, 
            {
                "PMID": "11056593", 
                "citation": "Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M, Vinik A, Giuliani M, Stevens JC, Barbano R, Dyck PJ. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA. 2000 Nov 1;284(17):2215-21."
            }, 
            {
                "PMID": "10889110", 
                "citation": "Bonini S, Lambiase A, Rama P, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology. 2000 Jul;107(7):1347-51; discussion 1351-2."
            }, 
            {
                "PMID": "9554857", 
                "citation": "Lambiase A, Rama P, Bonini S, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med. 1998 Apr 23;338(17):1174-80."
            }, 
            {
                "PMID": "19672199", 
                "citation": "Liu Q, McDermott AM, Miller WL. Elevated nerve growth factor in dry eye associated with established contact lens wear. Eye Contact Lens. 2009 Sep;35(5):232-7."
            }, 
            {
                "PMID": "8053664", 
                "citation": "Petty BG, Cornblath DR, Adornato BT, Chaudhry V, Flexner C, Wachsman M, Sinicropi D, Burton LE, Peroutka SJ. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol. 1994 Aug;36(2):244-6."
            }, 
            {
                "PMID": "17980361", 
                "citation": "Qi H, Li DQ, Shine HD, Chen Z, Yoon KC, Jones DB, Pflugfelder SC. Nerve growth factor and its receptor TrkA serve as potential markers for human corneal epithelial progenitor cells. Exp Eye Res. 2008 Jan;86(1):34-40. Epub 2007 Sep 15."
            }, 
            {
                "PMID": "11591856", 
                "citation": "Schifitto G, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra CM, Rubin M, Cohen BA, Tucker T, Koralnik IJ, Katzenstein D, Haidich B, Smith ME, Shriver S, Millar L, Clifford DB, McArthur JC; AIDS Clinical Trials Group Team 291. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology. 2001 Oct 9;57(7):1313-6."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01744704"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Domp\u00e9 s.p.a.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Domp\u00e9 s.p.a.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}